aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -73.7% | +293.4% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -73.7% over three years. Forward estimates point to Revenue at +293.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Relmada Therapeutics, Inc. NASDAQ:RLMD | $454.17M | $4.33 | Not rated | -9.6 | -28.01% |
ALX Oncology Holdings Inc. NASDAQ:ALXO | $269.13M | $2.00 | Not rated | -0.9 | -25.00% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $140.58M | $5.27 | Not rated | -40.8 | -33.02% |
Precision BioSciences, Inc. NASDAQ:DTIL | $99.80M | $7.78 | Not rated | -1.9 | +38.76% |
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | $88.17M | $2.06 | Not rated | -0.8 | -38.05% |
CAMP4 Therapeutics Corporation NASDAQ:CAMP | $88.15M | $4.15 | Not rated | -2.8 | +13.96% |
MindWalk Holdings Corp. NASDAQ:HYFT | $65.31M | $1.39 | Not rated | -8.1 | -38.98% |
Continue the stock analysis
Jump to another research area for this company.